Advertisement

The Role of New Experimental Conservative Therapies for High Risk Non-Muscle Invasive Bladder Cancer: Could We Trust Them?

  • M. Allasia
  • F. Soria
Chapter

Abstract

Despite adjuvant intravesical treatments, up to 40–50% of high-risk non-muscle invasive bladder cancer (NMIBC) patients will experience recurrence. The current evidence, due to the very aggressive behaviour of the disease, strongly recommends radical surgery for NMIBC patients failing intravesical immunotherapy (Bacillus Calmette-Guerin). However, on the other hand, radical surgery may sometimes represent an over-treatment, especially for those patients with non-high-grade recurrence. Moreover, some patients could be considered unfit for surgery due to the high comorbidity rates, as frequently observed in old patients. Therefore, the development of new adjuvant therapies, or at least the improvement of the existing ones is urgently needed. In the last years, several new device-assisted therapies have been developed with the aim to improve the effectiveness of intravesical chemotherapy by increasing its penetration into the bladder wall. Electromotive Drug Administration (EMDA) and chemo-hyperthermia (CHT) are, to date, the most investigated. Reported results are promising and showed that conservative therapies for high-risk NMIBC (CHT and EMDA) could represent a feasible and safe treatment, even if, due to the low level of evidence and to the lack of high-quality trials, remain, to date, experimental.

Keywords

Non-muscle invasive bladder cancer Intravesical immunotherapy BCG failure Electromotive drug administration Chemo-hyperthermia 

References

  1. 1.
    Gontero P, Bohle A, Malmstrom P-U, O’Donnell MA, Oderda M, Sylvester R, et al. The role of Bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol. 2010;57:410–29.  https://doi.org/10.1016/j.eururo.2009.11.023.CrossRefPubMedGoogle Scholar
  2. 2.
    Martin FM, Kamat AM. Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther. 2009;9:815–20.  https://doi.org/10.1586/era.09.35.CrossRefPubMedGoogle Scholar
  3. 3.
    Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–61.  https://doi.org/10.1016/j.eururo.2016.05.041.CrossRefPubMedGoogle Scholar
  4. 4.
    Phipps JB, Padmanabhan RV, Lattin GA. Iontophoretic delivery of model inorganic and drug ions. J Pharm Sci. 1989;78:365–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Kos B, Vásquez JL, Miklavčič D, Hermann GGG, Gehl J. Investigation of the mechanisms of action behind Electromotive Drug Administration (EMDA). Peer J. 2016;4:e2309.  https://doi.org/10.7717/peerj.2309.CrossRefPubMedGoogle Scholar
  6. 6.
    Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170:777–82.  https://doi.org/10.1097/01.ju.0000080568.91703.18.CrossRefPubMedGoogle Scholar
  7. 7.
    Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7:43–51.  https://doi.org/10.1016/S1470-2045(05)70472-1.CrossRefPubMedGoogle Scholar
  8. 8.
    Gan C, Amery S, Chatterton K, Khan MS, Thomas K, O’Brien T. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the standard intravesical regimen in high risk nonmuscle invasive bladder cancer: 2-year outcomes. J Urol. 2016;195:1697–703.  https://doi.org/10.1016/j.juro.2016.01.103.CrossRefPubMedGoogle Scholar
  9. 9.
    Di Stasi SM, Valenti M, Verri C, Liberati E, Giurioli A, Leprini G, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 2011;12(9):871.  https://doi.org/10.1016/S1470-2045(11)70190-5.CrossRefPubMedGoogle Scholar
  10. 10.
    Owusu RA, Abern MR, Inman BA. Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer. Biomed Res Int. 2013;2013:262313.  https://doi.org/10.1155/2013/262313.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Eppink B, Krawczyk PM, Stap J, Kanaar R. Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies. Int J Hyperth. 2012;28:509–17.  https://doi.org/10.3109/02656736.2012.695427.CrossRefGoogle Scholar
  12. 12.
    Slater SE, Patel P, Viney R, Foster M, Porfiri E, James ND, et al. The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer. Ann R Coll Surg Engl. 2014;96:415–9.  https://doi.org/10.1308/003588414X13946184901001.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21:4270–6.  https://doi.org/10.1200/JCO.2003.01.089.CrossRefPubMedGoogle Scholar
  14. 14.
    Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107:912–8.  https://doi.org/10.1111/j.1464-410X.2010.09654.x.CrossRefPubMedGoogle Scholar
  15. 15.
    Arends TJH, van der Heijden AG, Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol. 2014;192:708–13.  https://doi.org/10.1016/j.juro.2014.03.101.CrossRefPubMedGoogle Scholar
  16. 16.
    Halachmi S, Moskovitz B, Maffezzini M, Conti G, Verweij F, Kedar D, et al. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol. 2011;29:259–64.  https://doi.org/10.1016/j.urolonc.2009.02.012.CrossRefPubMedGoogle Scholar
  17. 17.
    van der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol. 2004;46:65–71; discussion 71-2.  https://doi.org/10.1016/j.eururo.2004.01.019.CrossRefPubMedGoogle Scholar
  18. 18.
    Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009;27:319–24.  https://doi.org/10.1007/s00345-009-0384-2.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Arends TJH, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with Mitomycin C versus Bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016;69(6):1046–52.  https://doi.org/10.1016/j.eururo.2016.01.006.CrossRefPubMedGoogle Scholar
  20. 20.
    Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology. 2004;63:466–71.  https://doi.org/10.1016/j.urology.2003.10.036.CrossRefPubMedGoogle Scholar
  21. 21.
    Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A, et al. Combined thermo-chemotherapy for recurrent bladder cancer after Bacillus Calmette-Guerin. J Urol. 2009;182:1313–7.  https://doi.org/10.1016/j.juro.2009.06.017.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • M. Allasia
    • 1
  • F. Soria
    • 2
  1. 1.Department of UrologyA.O. Città della salute e della Scienza di Torino, University of TurinTurinItaly
  2. 2.Department of Urology and Comprehensive Cancer CenterVienna General Hospital, Medical University of ViennaWienAustria

Personalised recommendations